rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Paul B. Manning

Director

Company insider

Files Form 4 as: Director and 10% owner, Candel Therapeutics; Director and 10% owner, Liquidia; Director and 10% owner, Verrica Pharmaceuticals; Director and 10% owner, Taysha Gene Therapies; 10% owner, Acumen Pharmaceuticals; Director and 10% owner, Dova Pharmaceuticals; Director and 10% owner, AveXis.

Every Form 4 they filed

In numbers

Trades disclosed
193
Buys
51
Sells
5
Bought
$123.1M
Sold
$54.5M
Companies
7
Companies where not an officer
7
First trade
10 Feb 2016
Last trade
30 Sep 2026
Last filed
2 Oct 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
CADL Candel TherapeuticsDirector, 10% owner · Biotechnology · last 30 Sep 20265 buys · 0 sells
LQDA LiquidiaDirector, 10% owner · Biotechnology · last 16 Jun 20264 buys · 4 sells
VRCA Verrica PharmaceuticalsDirector, 10% owner · Biotechnology · last 25 Nov 202520 buys · 0 sells
TSHA Taysha Gene TherapiesDirector, 10% owner · Biotechnology · last 30 May 202510 buys · 0 sells
ABOS Acumen Pharmaceuticals10% owner · Biotechnology · last 6 Jul 20211 buy · 0 sells
Dova PharmaceuticalsDirector, 10% owner · last 12 Nov 201911 buys · 0 sells
AveXisDirector, 10% owner · last 15 May 20180 buys · 1 sell

Activity over time

1 Nov 2024 – 1 Oct 2026
201Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
30 Sep 2026filed 2 Oct 2026CADL Candel Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A$19K2,189 at $8.68filing
30 Jun 2026filed 1 Jul 2026CADL Candel Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A$19K2,199 at $8.64filing
30 Jun 2026filed 1 Jul 2026CADL Candel Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A$19K2,199 at $8.64filing
23 Jun 2026filed 24 Jun 2026CADL Candel Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—32,000 at $0.00filing
23 Jun 2026filed 24 Jun 2026CADL Candel Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—32,000 at $0.00filing
16 Jun 2026filed 18 Jun 2026LQDA LiquidiaBiotechnologySEC FORM 4 Code A—5,882 at $0.00filing
16 Jun 2026filed 18 Jun 2026LQDA LiquidiaBiotechnologySEC FORM 4 Code A—5,882 at $0.00filing
4 Jun 2026filed 8 Jun 2026LQDA LiquidiaBiotechnologySEC FORM 4 Sold$727K11,513 at $63.13filing
4 Jun 2026filed 8 Jun 2026LQDA LiquidiaBiotechnologySEC FORM 4 Sold$5.7M88,487 at $64.28filing
4 Jun 2026filed 8 Jun 2026LQDA LiquidiaBiotechnologySEC FORM 4 Sold$1.2M19,125 at $62.62filing
4 Jun 2026filed 8 Jun 2026LQDA LiquidiaBiotechnologySEC FORM 4 Sold$4.4M68,265 at $63.83filing
4 Jun 2026filed 8 Jun 2026LQDA LiquidiaBiotechnologySEC FORM 4 Sold$812K12,610 at $64.42filing
4 Jun 2026filed 8 Jun 2026LQDA LiquidiaBiotechnologySEC FORM 4 Sold$727K11,513 at $63.13filing
4 Jun 2026filed 8 Jun 2026LQDA LiquidiaBiotechnologySEC FORM 4 Sold$5.7M88,487 at $64.28filing
4 Jun 2026filed 8 Jun 2026LQDA LiquidiaBiotechnologySEC FORM 4 Sold$1.2M19,125 at $62.62filing
4 Jun 2026filed 8 Jun 2026LQDA LiquidiaBiotechnologySEC FORM 4 Sold$4.4M68,265 at $63.83filing
4 Jun 2026filed 8 Jun 2026LQDA LiquidiaBiotechnologySEC FORM 4 Sold$812K12,610 at $64.42filing
31 Mar 2026filed 2 Apr 2026CADL Candel Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A$19K4,618 at $4.11filing
31 Mar 2026filed 2 Apr 2026CADL Candel Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A$19K4,618 at $4.11filing
23 Feb 2026filed 26 Feb 2026CADL Candel TherapeuticsBiotechnologySEC FORM 4 Bought$3.0M550,458 at $5.45filing

Sectors

Health Care44
Not placed12

Buys in green, sells in red, by the company’s sector.

Related people

Russell SchundlerGeneral Counsel · General Counsel at Liquidia, filing Form 4 there in the last year
Roger JeffsChief Executive Officer · Chief Executive Officer at Liquidia, filing Form 4 there in the last year
Sanjeev KhindriChief Development Officer · Chief Development Officer at Liquidia, filing Form 4 there in the last year
Sarah KreppChief Human Resource Officer · Chief Human Resource Officer at Liquidia, filing Form 4 there in the last year
Dana BoyleChief Accounting Officer · Chief Accounting Officer at Liquidia, filing Form 4 there in the last year
Jason AdairChief Business Officer · Also traded LQDA in the last 90 days
Michael KasetaCFO and COO · Also traded LQDA in the last 90 days
Rajeev SaggarChief Medical Officer · Also traded LQDA in the last 90 days